diranersen

all catalysts(0)

nothing on the calendar yet

News(10)

• Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
  Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.
  biospace · 4d ago
• Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
  With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
  biospace · 15d ago
• Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations
  Biogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.
  biospace · 16d ago
• ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
  Biogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.
  fiercebiotech · 16d ago
• STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
  An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines
  stat · 1mo ago
• STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows
  An experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.
  stat · 1mo ago
• Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
  The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
  biopharma_dive · 1mo ago
• STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
  Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter.
  stat · 1mo ago
• Biogen pushing tau drug forward despite Alzheimer’s study failure
  One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
  biopharma_dive · 3mo ago
• STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
  Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau
  stat · 3mo ago